BBC241220P27000
- 0.00
- 0.000.00%
Etfis Ser Tr I Virtus Lifesci Biotech Clinical Trials Newsroom
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Bright Minds Initiated at Outperform by Baird, Longboard Takeover Cited
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $50
12 Health Care Stocks Moving In Monday's Pre-Market Session
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Recursion Pharmaceuticals Analyst Ratings
Trump Media Saw the Largest Increase in Short Interest in October
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target
Summit Therapeutics Analyst Ratings
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars
Arm Falls 6%: Nvidia 13F Shows Decreased Stake In Arm Holdings By 13%
Nvidia Discloses New Stake in Applied Digital; Maintains Arm Holdings, SoundHound Stakes
Merck to Buy Rights to Chinese Cancer Drug for up to $3.3B
Disc Medicine Analyst Ratings